
Pregnant Women Issued Drinking Water Warning
Pregnant women have been advised to use water filters by experts who spoke to Newsweek after a study found levels of arsenic in water systems considered safe are impacting birth outcomes,
A national study led by researchers at Columbia University evaluated risks from 13,998 pregnancies across 35 cohort sites participating in the National Institutes of Health's Environmental influences on Child Health Outcomes (ECHO) program, and published its findings on the medical journal site JAMA Network last week.
The researchers discovered that prenatal exposure to arsenic was associated with a higher likelihood of babies being born preterm with lower birth weights, factors that they said are important "predictors of infant mortality and morbidity across the life span."
This was the case even at the level of exposure the Environmental Protection Agency (EPA) currently deems safe, 10 micrograms per liter, a regulation that was established in 2001 and has not been changed since.
Arsenic is a natural element found in soils, sediments, and groundwater, meaning it can feed into public drinking water systems.
While this study highlights concerns of arsenic exposure in relation to pregnancy and birth outcomes in particular, the contaminant poses health risks to any individual.
In the Centers for Disease Control and Prevention (CDC) toxicology report on arsenic, the agency notes, "it is widely accepted that arsenic is carcinogenic," and that "numerous epidemiological studies have examined associations between exposure to arsenic in drinking water and various health outcomes."
"Arsenic can cause a variety of cancers, including cancer of the bladder and urothelium, gastrointestinal tract, kidney, liver, lung, pancreas, and skin; as well as cardiovascular effects, and neurologic effects," Brett A. Poulin, a professor in the Department of Environmental Toxicology at the University of California, Davis, told Newsweek via email in response to the study.
States also have different exposure levels, the study said, with Michigan, South Dakota, Nevada, and California all having areas with levels of higher than 5 micrograms per liter of arsenic in drinking water systems.
"Arsenic levels tend to be higher in drinking water that comes from groundwater sources, such as community wells or private household wells," Poulin said. "In many cases, the arsenic comes from natural minerals in the aquifer—especially in regions with sedimentary rocks or glacial deposits that contain arsenic-bearing materials."
He added that people living in areas that depend heavily on groundwater, and have geology rich in arsenic-containing sediments, are more likely to have elevated arsenic in their drinking water.
Asked whether the agency believes the level of arsenic exposure considered safe needed to be updated following the release of the study, an EPA spokesperson told Newsweek that determining a safe level of exposure requires a consideration of implementation and cost, as well as public health.
"The Maximum Contaminant Level Goal (MCLG) established under the Safe Drinking Water Act (SDWA) is set at zero for arsenic," the spokesperson said.
The MCLG is identified in the act as the maximum level of a contaminant in drinking water at which "no known or anticipated adverse effect on the health of persons would occur, allowing an adequate margin of safety," they added.
However, MCLGs are "non-enforceable public health goals," the spokesperson said. "MCLGs consider only public health, therefore, they sometimes are set at levels which water systems cannot meet due to technical limitations."
The spokesperson said the act requires the EPA to set the enforceable Maximum Contaminant Level (MCL) "as close as feasible to the MCLG taking cost into consideration."
Therefore, in its determination of a MCL of 10 micrograms per liter of arsenic exposure, the EPA had to evaluate the impact on costs and on public health, in a "health risk reduction and cost analysis."
The spokesperson added that the EPA regularly reviews National Primary Drinking Water Regulations and "evaluates whether there are new peer reviewed health assessments for a contaminant."
According to the spokesperson, in July 2024 under the Biden administration, the agency "completed the fourth cyclical review of drinking water regulations and determined that arsenic was not a candidate for revision at the time."
"The Biden Administration noted that a regulatory revision for arsenic was not appropriate because the reassessment of the health risks resulting from exposure to arsenic was ongoing," the EPA spokesperson said.
Although, in light of the study, Poulin said: "One thing the EPA must consider when revising MCLs is feasibility of achieving a more stringent MCL."
"There is no such thing as completely safe water, whether it is bottled or tap water," Marc Edwards, a professor in civil and environmental engineering at Virginia Tech, told Newsweek.
Although, he added this new research should be "considered in future revisions of the regulated arsenic level."
Given the impact of even accepted levels of arsenic exposure on pregnancy and birth, experts have advised expecting mothers at risk of higher exposure to use water filters.
"In situations with high risk of lead or arsenic, filters are recommended," Edwards said.
"Waters with elevated arsenic are relatively rare compared to the problem of lead, and can be identified by reading your water companies consumer confidence report," he added.
"This research underscores our responsibility as a society to protect the health of pregnant women," Marci Lobel, a professor in the Department of Obstetrics, Gynecology and Reproductive Medicine at Stony Brook University, New York, told Newsweek.
"Clearly, we must reduce arsenic levels in public water supplies," she said and advised pregnant women to filter their water if possible.
Although, Lobel added that "pregnant women should not be unduly alarmed," as despite the study's findings, which are a "serious concern," the impacts are "not large."
"We should consider the results of this important study in the context of what we already know about reducing health risks for pregnant women," she added.
"It is well known that pregnancy is a highly vulnerable time for environmental exposures to have an impact on pregnant women and their babies," Natalie Exum, a professor in the Department of Environmental Health and Engineering at Johns Hopkins Bloomberg School of Public Health, told Newsweek.
She added that she was "concerned" about the findings of the study, and that they indicate that the "current regulation set in the Safe Drinking Water Act may not be protecting maternal and child health."
"If you are pregnant and living in an area where there are detectable levels of arsenic in the drinking water, it would be best to use a filter that removes the arsenic to non-detectable levels," she said.
Related Articles
RFK Jr. Says 'More Cavities' Due to No Fluoride in Water Is 'a Balance'Hidden Danger in Drinking Water Revealed in New StudyUS States Issued Drinking Water WarningMap Shows States Where Drinking Water Contamination is Highest
2025 NEWSWEEK DIGITAL LLC.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
A new AI breakthrough helped one couple get pregnant after 19 years—here's what it could mean for others
For nearly 19 years, Rosie and her husband tried to grow their family. Their journey spanned 15 IVF cycles, countless doctor visits, and emotional highs and lows that left them exhausted but still hopeful. Each attempt came with the quiet ache of disappointment. Still, they held onto their dream. In March 2025, something changed. Doctors at Columbia University Fertility Center helped the couple achieve what had always felt just out of reach—a successful pregnancy. What made the difference wasn't a new medication or procedure, but a scientific advance that sounded almost improbable: artificial intelligence. A novel AI-powered tool, developed by a team led by Dr. Zev Williams, found what doctors had never been able to detect in her husband's semen sample—viable sperm. That discovery led to the first pregnancy in the world using this new technology. Fertility care has long focused on women, despite male factors contributing to nearly 40% of infertility cases. Azoospermia—a condition where no sperm are found in the ejaculate—is among the most challenging to treat. Even with advanced microscopes, sperm can be nearly impossible to detect, and options are often limited to surgery or donor sperm. For many couples, especially those with religious or cultural reasons to avoid donor conception, that leaves few alternatives. This gap in care reflects deeper assumptions in reproductive medicine, where male fertility is often underexamined. The system, called STAR, is designed specifically to help address cases of azoospermia in a noninvasive and sperm-preserving way—offering a long-overdue shift in how male infertility is approached. Related: The Truth about Men's Infertility To tackle azoospermia, researchers at Columbia University developed a system called STAR (Sperm Track and Recovery). It uses artificial intelligence and a microfluidic chip to scan millions of microscopic images, identifying and isolating rare sperm that would otherwise go unnoticed. If sperm are detected, the system isolates and collects them—gently enough for use in IVF. In tests, STAR found dozens of sperm in samples that human embryologists had spent days analyzing without success. The inspiration came from astronomy, where AI helps spot new stars in a sky full of noise. Here, the system scans semen samples with similar precision. When STAR detects sperm, it diverts that tiny portion for collection—preserving viable cells for fertilization. In one early test, embryologists spent two days combing through a sample without success. STAR found 44 sperm in under an hour. It's opening doors for couples who were once told they had no options—offering more than just speed. This marks the first reported case where AI has been used not only to detect sperm in complex samples, but also to physically recover them for use in fertility treatment—offering new hope to families who previously had few or no options. Related: It's time to stop calling infertility a women's health issue For nearly two decades, Rosie and her husband dreamed of starting a family. After 15 unsuccessful IVF cycles and years of searching for answers, they were told that her husband's azoospermia left them with few options beyond using donor sperm—something they weren't ready to accept. Then they heard about STAR. Through a community group, Rosie connected with Dr. Zev Williams' team and learned about the new AI technology. For the first time, there was a tool that could potentially find viable sperm in a noninvasive, chemical-free way. That was enough to give them the courage to try one more cycle. This time, STAR found sperm—enough to fertilize Rosie's eggs. Just days later, she got the call she never thought she'd receive: she was pregnant. Now four months along, she says she still wakes up in disbelief. But the scans are real—and so is her baby. Related: The powerful documentary 'One More Shot' captures infertility on film like never before The success of STAR marks a technological milestone and signals a new frontier in understanding and treating infertility. Traditionally, couples facing azoospermia had few options beyond donor sperm. Now, STAR offers a potential path forward by making it possible to locate and retrieve even extremely rare sperm without damaging them. Here's what STAR could mean for the future of fertility care: Faster, more precise sperm selection: STAR scans millions of frames per hour, identifying and isolating viable sperm in real time. Expanded options for couples facing male-factor infertility: The technology may help those who were previously told they had no viable options. Less reliance on invasive or costly procedures: By improving sperm detection, STAR could reduce the need for more aggressive interventions. A shift in how infertility is approached clinically: STAR's success could signal a broader rethinking of diagnostic and treatment pathways. Potential to democratize access to advanced fertility care: As the technology becomes more scalable, it may increase availability and affordability. As Dr. Zev Williams explains, this AI doesn't replace the human touch; it extends it. With STAR, the goal is to give couples facing daunting odds a better chance—something that's long felt out of reach. AI is quietly transforming the way fertility challenges are understood and treated. Tools like STAR aren't science fiction—they're already helping families who've spent years navigating heartbreak and uncertainty. By spotting what even the most skilled eyes can miss, AI is opening new doors in cases that once seemed hopeless. For parents and parents-to-be, this isn't just about technology—it's about renewed possibility. As research continues, innovations like STAR could offer more families the chance to grow, with less guesswork and more hope.


Newsweek
5 hours ago
- Newsweek
Americans Advised To Avoid the Sun in 15 States This Weekend
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Fifteen states will experience elevated ultraviolet (UV) radiation levels this weekend, according to the National Weather Service (NWS) and the Environmental Protection Agency (EPA). Why It Matters The EPA said that elevated UV radiation levels greatly increase the risk of skin burns, eye damage and long-term health problems like skin cancer. What To Know The UV index runs on a scale of one to 11. The levels, and their corresponding advice, are: 1-2: Low (minimal risk from UV rays for the average person) Wear sunglasses on bright days. In winter, snow can reflect UV and nearly double exposure. Use SPF 30+ sunscreen if you burn easily. 3-5: Moderate (moderate risk of harm from unprotected sun exposure) Cover up, wear a hat and sunglasses. Use SPF 30+ sunscreen. Stay in the shade near midday when the sun is strongest. 6-7: High (high risk of harm from unprotected sun exposure) Limit sun time between 10 a.m. and 4 p.m. Wear protective clothing, sunglasses, and SPF 30+ sunscreen. 8-10: Very High (very high risk of harm; sun protection is essential) Take extra precautions including wide-brimmed hats and long sleeves. Minimize exposure between 10 a.m. and 4 p.m. Be aware: white sand and similar surfaces reflect UV and increase exposure. 11+: Extreme (extreme risk of harm; unprotected skin can burn in minutes) Avoid sun exposure from 10 a.m. to 4 p.m. Reapply SPF 30+ sunscreen every 2 hours. Seek shade, wear full coverage, and use sun protection. A forecast map shows which areas could see the highest UV levels on Saturday. A forecast map shows which areas could see the highest UV levels on Saturday. EPA According to the EPA's UV index forecast for Saturday, solar noon—when the sun is at its highest point in the sky at a specific location—parts of Nevada, California, Arizona, Utah, New Mexico, Colorado, Texas, Oklahoma, Arkansas, Louisiana, Missouri, Kansas and Wyoming could see levels of at least 11. On Sunday, Florida and Mississippi were expected to see similar UV levels in addition to the other states, while Nebraska and Missouri will experience UV levels below 11. A forecast map shows which areas could see the highest UV levels on Sunday. A forecast map shows which areas could see the highest UV levels on Sunday. EPA What People Are Saying Anthony Young, emeritus professor of experimental photobiology, dermatology, at King's College, London, previously told Newsweek: "The UV index [UVI] is a measure of the sunburning power of higher the UVI, the shorter the time you need in the sun to burn." Richard Weller, professor of medical dermatology, at the U.K.'s University of Edinburgh, previously told Newsweek that sunlight can cause photoaging—premature aging of the skin as a result of prolonged and repeated exposure to UV radiation, adding: "Sunburn is a risk factor for melanoma skin cancer, which is the most serious of the skin cancers." What Happens Next The UV index forecast map is generated each day using data from the NWS.


Business Wire
5 hours ago
- Business Wire
Foldax Announces Positive One-Year Data on TRIA Mitral Valve
SALT LAKE CITY--(BUSINESS WIRE)--Foldax® Inc., a leader in the development of innovative polymer heart valves, today announced compelling one-year results from the India Clinical Trial of the TRIA™ Mitral Valve, showing a good safety profile, sustained hemodynamic performance, and statistically significant improvement in patient quality of life. These are the first one-year outcomes ever presented for a multicenter clinical study of a polymer heart valve worldwide. Results were presented today at New York Valves 2025, the annual conference organized by the Cardiovascular Research Foundation (CRF), and concurrently published in the Journal of the American College of Cardiology (JACC). 'It is exciting to see the positive clinical outcomes associated with this novel polymer valve.' Isaac George, M.D., Surgical Director of the Heart Valve Center at Columbia University. Share Key one-year results from the trial showed: No valve-related mortality or reinterventions >50% reduction in mean gradient (9.7 mmHg to 4.5 mmHg) and >90% increase in effective orifice area (0.9 cm² to 1.5 cm²), the highest reported in similar surgical mitral valve studies 24-point improvement in KCCQ score (57.5 to 81.9) and 65% increase in Six-Minute Walk Test distance (298.1 m to 494.8 m), indicating significant improvement in quality of life The prospective, multicenter trial enrolled 67 patients aged 19 to 67 across eight sites in India, with an average age of 42. Notably, 64% were women, and of these, nearly half were of childbearing age, a significantly larger percentage than typically seen in clinical studies. Seventy-three percent of patients had rheumatic heart disease. 'It is exciting to see the positive clinical outcomes associated with this novel polymer valve,' said Isaac George, M.D., Surgical Director of the Heart Valve Center at Columbia University. 'This new type of valve sets out to reimagine how a device can address clinical needs that are underserved by current valve solutions.' 'I am proud to be the principal investigator in India for this groundbreaking trial and represent the highly esteemed clinical investigators who participated in the study,' said Kaushal Pandey, M.D., Principal Investigator of the TRIA Mitral Valve India Clinical Trial and Cardiac Surgeon at P.D. Hinduja Hospital in Mumbai. 'The TRIA Mitral Valve provides hope for Indian patients—including younger patients and many women of childbearing age—for whom current valve options often fall short.' Foldax's vision for its novel polymer heart valves is to address the limitations of tissue and mechanical options by making its valves durable, with the future goal of avoiding a requirement for lifelong anticoagulation. TRIA valves incorporate a proprietary polymer—LifePolymer™ —formulated to be calcium-resistant, biostable and biocompatible. The novel polymer material enables TRIA valves to be robotically produced, which is designed to increase manufacturing efficiency and maximize product quality and precision. 'These results validate our strategy of taking heart valve therapy to a new level by bringing innovation to a platform of products that will help patients globally,' said Ken Charhut, CEO of Foldax. The Journal of the American College of Cardiology (JACC) publication can be viewed at: *The TRIA Mitral Valve is approved for use in India by CDSCO. The TRIA Mitral Valve is for investigational use only and is not available for commercial sale in the U.S. Headquartered in Salt Lake City, Utah, Foldax is reinventing every aspect of the heart valve—from material to design to manufacturing—to develop surgical and transcatheter valves with the potential to last a lifetime, addressing limitations of tissue and mechanical valves. Foldax investors include Angel Physicians Fund, Biostar Capital, Caltech, Glenview Capital, Kairos Ventures, Memorial Care Innovation Fund and Sayan Bioventures. For more information on the TRIA Mitral Valve and Foldax's commitment to revolutionizing heart valve care, visit